Chikungunya Virus Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for detecting and treating Chikungunya virus infections, with limited human monoclonal antibodies available that provide substantial neutralizing activity against the virus.
Innovation Solution
Development of monoclonal antibodies with clone-paired heavy and light chain CDR sequences that specifically bind to Chikungunya virus glycoprotein E2, which can be used for detection and treatment by administering them to subjects through various routes, including genetic delivery with RNA or DNA sequences, and their use in recombinant forms such as ScFv, Fab, or F(ab′)2 fragments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If limited human monoclonal antibodies are used for CHIKV detection and treatment, then diagnostic and therapeutic options are restricted, but developing new antibodies requires significant time and resources
Solution Approach 1:
The patent performs preliminary actions by identifying and characterizing multiple human monoclonal antibodies (4J21, 4N12, 2H1, 6D4, 5G3) with neutralizing activity against CHIKV before clinical need arises. These antibodies are fully characterized with their epitope specificities, neutralization mechanisms, and cross-reactivity profiles established in advance, so they are ready for immediate deployment when outbreaks occur, eliminating the need for rapid de novo antibody development during emergencies.
Solution Approach 2:
The patent develops a universal panel of monoclonal antibodies that can detect and neutralize multiple CHIKV strains and genotypes (Asian, African, and American strains). The antibodies target conserved epitopes on the E2 glycoprotein that are preserved across different viral variants, providing broad-spectrum protection and diagnostic capability without requiring strain-specific antibody development.
2Reliability
If existing monoclonal antibodies with modest neutralizing activity are used, then treatment efficacy is limited, but developing ultrapotent antibodies requires extensive screening and characterization
Solution Approach 1:
The patent systematically evaluates multiple parameters to identify ultrapotent antibodies: neutralization potency (IC50 values), epitope accessibility, cross-strain reactivity, and mechanism of action (blocking viral attachment versus fusion). By establishing comprehensive characterization protocols that measure these parameters, the patent identifies antibodies like 4J21 and 4N12 with IC50 values in the low nanogram per milliliter range, representing a significant improvement over previously available antibodies with modest activity.
Solution Approach 2:
The patent segments the complex task of antibody development into distinct phases: initial screening of hybridoma supernatants for neutralizing activity, followed by epitope mapping using peptide arrays and mutational analysis, then mechanistic studies to determine whether antibodies block attachment or fusion, and finally potency determination through dose-response curves. This segmented approach makes the overall complex process manageable and systematic.
3Adaptability or versatility
If monoclonal antibodies are developed for both detection and treatment, then dual-purpose utility is achieved, but requires comprehensive characterization for both diagnostic and therapeutic applications
Solution Approach 1:
The patent develops monoclonal antibodies with dual utility by characterizing them for both diagnostic and therapeutic applications using the same antibody panel. The antibodies are evaluated for diagnostic sensitivity and specificity in detecting CHIKV infection, and simultaneously for therapeutic potency and mechanism of action in neutralizing viral infection. This universal characterization approach allows the same antibodies to serve both diagnostic and therapeutic purposes, maximizing resource efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively neutralize Chikungunya virus infectivity and can be used for both diagnosis and treatment, demonstrating ultrapotent activity in preventing viral fusion and reducing infection severity, even when administered after infection.
Implementation Method 1
contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and detecting Chikungunya virus glycoprotein E2 in said sample by binding of said antibody or antibody fragment to E2 in said sample
Data Source
AI summary
The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.